Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Myovant Sciences Ltd (MYOV)

Myovant Sciences Ltd (MYOV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,409,786
  • Shares Outstanding, K 89,624
  • Annual Sales, $ 0 K
  • Annual Income, $ -273,550 K
  • 60-Month Beta 2.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 82.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.81
  • Number of Estimates 4
  • High Estimate -0.77
  • Low Estimate -0.84
  • Prior Year -1.04
  • Growth Rate Est. (year over year) +22.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.74 +163.41%
on 11/14/19
19.58 -22.78%
on 12/03/19
+9.02 (+147.87%)
since 11/13/19
3-Month
4.14 +265.22%
on 10/29/19
19.58 -22.78%
on 12/03/19
+8.95 (+145.06%)
since 09/13/19
52-Week
4.14 +265.22%
on 10/29/19
26.02 -41.89%
on 04/03/19
-2.80 (-15.63%)
since 12/13/18

Most Recent Stories

More News
Biotech Tops in November: Best ETFs & Stocks

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

CNCR : 23.03 (-0.54%)
BBC : 36.00 (-1.15%)
BBP : 43.45 (-0.21%)
GBT : 76.75 (-0.18%)
PTI : 4.32 (+5.37%)
VRTX : 219.32 (-0.56%)
CLVS : 13.03 (-2.98%)
MYOV : 14.98 (-4.77%)
CNST : 38.74 (-0.87%)
KRTX : 68.96 (-6.19%)
CRSP : 65.09 (-1.42%)
ARKG : 34.28 (-0.67%)
GNOM : 16.14 (+1.21%)
Is the Options Market Predicting a Spike in Myovant (MYOV) Stock?

Investors need to pay close attention to Myovant (MYOV) stock based on the movements in the options market lately.

MYOV : 14.98 (-4.77%)
Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant's President and CEO,...

MYOV : 14.98 (-4.77%)
Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

CELG : 108.24 (+0.10%)
VRTX : 219.32 (-0.56%)
ALKS : 20.98 (-1.27%)
VTGN : 0.65 (+14.04%)
MYOV : 14.98 (-4.77%)
KRTX : 68.96 (-6.19%)
CRSP : 65.09 (-1.42%)
Why the Global Pain Management Drug Market is Adopting More Non-Opioid Options

It appears that the reign of the opioid drugs in the global pain management markets could be coming to an end. While opioids have long been the 'best' choice to address the pain patients suffer from various...

QBIO : 1.4600 (+4.29%)
MYOV : 14.98 (-4.77%)
HRTX : 25.58 (+0.08%)
BCRX : 2.89 (-2.36%)
ENDP : 4.65 (-1.06%)
Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer

-- Primary efficacy endpoint met with 96.7% of men achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks

MYOV : 14.98 (-4.77%)
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer

Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced it will hold a webcast and conference call beginning...

MYOV : 14.98 (-4.77%)
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019

-Landmark Agreement with Sumitomo Dainippon Pharma to provide major financial backing and safeguards for minority shareholders

MYOV : 14.98 (-4.77%)
Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders

-- Sumitomo Dainippon Pharma to provide Myovant Sciences with a $350 million, low-interest, five-year term loan facility, with no repayments due until the end of the term

MYOV : 14.98 (-4.77%)
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis

-- Top-line results for SPIRIT 2 and SPIRIT 1 expected in the first and second quarters of 2020, respectively

MYOV : 14.98 (-4.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade MYOV with:

Business Summary

Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral...

See More

Key Turning Points

2nd Resistance Point 16.47
1st Resistance Point 16.10
Last Price 15.00
1st Support Level 15.46
2nd Support Level 15.19

See More

52-Week High 26.02
Fibonacci 61.8% 17.66
Fibonacci 50% 15.08
Last Price 15.00
Fibonacci 38.2% 12.50
52-Week Low 4.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar